Skip to main content

Table 1 Descriptive characteristics of enrolled patients

From: The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period

 

NON-T2D

T2D

N

1748 (16.3%)

8981 (83.7%)

Age (years)

63.8 [0.14]

63.8 [0.07]

Male gender (%)

1148 (65.7%)

5063 (56.4%)

Screening data and medication:

  

Weight (kg)

95.0 [0.35]

96.3 [0.16]

Waist Circumference men (cm)

112.5 [0.30]

114.8 [0.15]

Waist Circumference women (cm)

104.3 [0.46]

110.0 [0.18]

Hip Circumference men (cm)

110.8 [0.28]

112.6 [0.14]

Hip Circumference women (cm)

116.7 [0.45]

119.1 [0.19]

Body Mass Index (kg/m2)

33.4 [0.10]

34.6 [0.05]

Systolic Blood Presurre (mmHg)

136.3 [0.31]

138.6 [0.13]

Diastolic Blood Pressure (mmHg)

78.4 [0.20]

77.6 [0.09]

Pulse rate (b.p.m.)

68.0 [0.23]

71.7 [0.11]

LDL-C (mmol/L)

3.00 [0.02]

2.81 [0.01]

HDL-C (mmol/L)

1.25 [0.007]

1.18 [0.003]

VLDL-C (mmol/L)

0.86 [0.008]

0.95 [0.004]

TC (mmol/L)

5.13 [0.03]

5.01 [0.01]

Triglycerides (mmol/L)

1.98 [0.03]

2.31 [0.02]

Statins

73.0%

64.2%

Fibrates

5.7%

10.3%

Betablockers

69.1%

58.5%

ACEi

63.8%

79.4%

Smoking at screening

10.3%

9.6%

Drinking at screening

63.4%

53.5%

Patient history of:

  

Stroke

9.2%

8.3%

Peripheral artery disease (PAD)

8.2%

11.4%

Coronary artery disease (CAD)

91.5%

60.8%

Acute Myocardial Infarction (AMI)

58.8%

37.1%

Congestive heart failure (CHF)

9.2%

8.4%

Hyperlipidemia

76.2%

81.8%

Hypertension

73.2%

90.7%

  1. Presented are means with standard error of the mean within [].
  2. 13 patients with unknown risk category were excluded.
  3. N denotes number of patients.
  4. Dichotomous values are presented as percentages.
  5. ACEi denotes angiotensin converting enzyme inhibitor.
  6. Smoking at screening is defined as current tobacco use.
  7. Drinking at screening is defined as at least 3 drinks per year.